Search
Search
GenScript
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 2
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Tocilizumab also known as atlizumab, is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration. It has a high affinity to IL-6R and blocks the IL-6 signaling by preventing the formation of the IL-6/IL-6R complex. Tocilizumab is used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. Anti-Tocilizumab Antibody (6C10), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Tocilizumab.
Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below.
Tocilizumab (Actemra) is a humanized monoclonal antibody that is developed by Hoffmann-La Roche and Chugai for the treatment of patients with rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. Tocilizumab binds to the interleukin-6 receptor (IL-6R) and blocks its interaction with interleukin 6 (IL-6), hindering IL-6 from exerting its pro-inflammatory effects.
仅用于科研。不用于诊断过程。未经明确授权不得转售。